Clozapine monitoring at a specialised psychiatric hospital: A retrospective chart review

BACKGROUND: Clozapine is the only Food and Drug Administration (FDA) and National Institute for Care and Excellence (NICE) approved drug for treatment-resistant schizophrenia (TRS). Its potentially life-threatening haematological side effects of neutropaenia and agranulocytosis mandate rigorous moni...

Descripción completa

Detalles Bibliográficos
Autores principales: Daniels, Michelle V., Ramlall, Suvira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AOSIS 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10623633/
https://www.ncbi.nlm.nih.gov/pubmed/37928939
http://dx.doi.org/10.4102/sajpsychiatry.v29i0.2039

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10623633/
https://www.ncbi.nlm.nih.gov/pubmed/37928939
http://dx.doi.org/10.4102/sajpsychiatry.v29i0.2039

Ejemplares similares